What's in Olympus Biotech Corporation's pipeline?

Olympus Biotech Corporation has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Olympus Biotech Corporation's portfolio?

Top competitors by shared drug class: Amgen, Austin Institute for Clinical Research.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/olympus-biotech-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Olympus Biotech Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olympus Biotech Corporation pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Trafermin 0.01% spray	Trafermin 0.01% spray	phase 3	growth factor	FGF-2	Wound healing

Therapeutic area mix

Wound healing · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Austin Institute for Clinical Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Olympus Biotech Corporation:

Cite this brief

Drug Landscape (2026). Olympus Biotech Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/olympus-biotech-corporation. Accessed 2026-05-16.